ID   NB4-DR1
AC   CVCL_U085
SY   NB4-R1
DR   Wikidata; Q54907529
RX   PubMed=9342843;
RX   PubMed=9716606;
RX   PubMed=11704857;
CC   Sequence variation: PML-RARA gene fusion (from parent cell line).
CC   Sequence variation: Heterozygous for KRAS p.Ala18Asp (c.53C>A) (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Arg248Gln (c.743G>A) (ClinVar=VCV000012356) (from parent cell line).
CC   Derived from sampling site: Bone marrow.
DI   NCIt; C3182; Acute promyelocytic leukemia with PML-RARA
DI   ORDO; Orphanet_520; Acute promyelocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0005 ! NB4
SX   Female
AG   23Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 02-07-20; Version: 11
//
RX   PubMed=9342843; DOI=10.1046/j.1432-0436.1997.6150321.x;
RA   Nason-Burchenal K., Maerz W., Albanell J., Allopenna J., Martin P.,
RA   Moore M.A., Dmitrovsky E.;
RT   "Common defects of different retinoic acid resistant promyelocytic
RT   leukemia cells are persistent telomerase activity and nuclear body
RT   disorganization.";
RL   Differentiation 61:321-331(1997).
//
RX   PubMed=9716606; DOI=10.1182/blood.V92.5.1758;
RA   Nason-Burchenal K., Allopenna J., Begue A., Stehelin D.,
RA   Dmitrovsky E., Martin P.;
RT   "Targeting of PML/RARalpha is lethal to retinoic acid-resistant
RT   promyelocytic leukemia cells.";
RL   Blood 92:1758-1767(1998).
//
RX   PubMed=11704857; DOI=10.1038/sj.onc.1204863;
RA   Roussel M.J., Lanotte M.;
RT   "Maturation sensitive and resistant t(15;17) NB4 cell lines as tools
RT   for APL physiopathology: nomenclature of cells and repertory of their
RT   known genetic alterations and phenotypes.";
RL   Oncogene 20:7287-7291(2001).
//